Literature DB >> 25020276

Metastin levels in relation with hormonal and metabolic profile in patients with polycystic ovary syndrome.

S A Yilmaz1, O S Kerimoglu2, A T Pekin2, F Incesu2, N U Dogan3, C Celik2, A Unlu4.   

Abstract

OBJECTIVE: The aim of the present study was to evaluate serum concentrations of metastin in relation with hormonal and metabolic profile in patients with and without polycystic ovary syndrome (PCOS). STUDY
DESIGN: The study was a clinical study. Eighty-three women with PCOS and 66 body mass index (BMI) matched controls were divided into two groups, based on BMI: overweight and obese (BMI≥25 kg/m(2)) and normal weight. (BMI<25 kg/m(2)) Hirsutism scores, hormonal and metabolic profile as well as metastin levels were evaluated in each subject. Blood samples were collected in the early follicular phase (between day 2 and day 5 of the menstrual cycle) at 9:00 AM, after an overnight fast. Circulating levels of LH, FSH, PRL, TSH, T, fT, DHEAS, 17-OH-P, sex hormone-binding globulin (SHBG), insulin, glucose, lipid profile and metastin were measured.
RESULTS: Metastin levels were significantly higher in the PCOS group compared to controls (2.02 ng/ml versus 1.16 ng/ml, p<0.001). Metastin levels correlated significantly positively with luteinizing hormone (LH), total testosterone (T), dehydroepiandrosteronesulphate (DHEA-SO4) levels, modified Ferriman-Gallwey (mFG) scores and free androgen index (FAI); however, correlated negatively with sex hormone binding globulin (SHBG) levels (p<0.05). When overweight or obese (BMI≥25 kg/m(2)) and normal weight (BMI<25 kg/m(2)) women with PCOS were compared to body mass index (BMI) matched controls, higher metastin levels were also found in PCOS groups (1.94 ng/ml versus 1.18 ng/ml, and 2.06 ng/ml versus 1.08 ng/ml, p<0.05, respectively).
CONCLUSIONS: These findings suggest that metastin levels were higher in women with PCOS as compared to controls regardless of BMI. Furthermore, metastin levels can be used as a specific marker for androgenic profile and this marker might play a role in the pathogenesis of PCOS.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Insulin resistance; Kisspeptin; Metastin; PCOS

Mesh:

Substances:

Year:  2014        PMID: 25020276     DOI: 10.1016/j.ejogrb.2014.06.004

Source DB:  PubMed          Journal:  Eur J Obstet Gynecol Reprod Biol        ISSN: 0301-2115            Impact factor:   2.435


  6 in total

1.  rs4889 polymorphism in KISS1 gene, its effect on polycystic ovary syndrome development and anthropometric and hormonal parameters in Saudi women.

Authors:  Fadwa S Albalawi; Maha H Daghestani; Mazin H Daghestani; Abdelmoneim Eldali; Arjumand S Warsy
Journal:  J Biomed Sci       Date:  2018-05-30       Impact factor: 8.410

Review 2.  Multiomics Analysis-Based Biomarkers in Diagnosis of Polycystic Ovary Syndrome.

Authors:  Shikha Rani; Piyush Chandna
Journal:  Reprod Sci       Date:  2022-01-27       Impact factor: 3.060

Review 3.  New markers of insulin resistance in polycystic ovary syndrome.

Authors:  K Polak; A Czyzyk; T Simoncini; B Meczekalski
Journal:  J Endocrinol Invest       Date:  2016-07-29       Impact factor: 4.256

4.  Sex-specific association between urinary kisspeptin and pubertal development.

Authors:  Rafaella Sales de Freitas; Thiago F A França; Sabine Pompeia
Journal:  Endocr Connect       Date:  2022-09-26       Impact factor: 3.221

5.  Kisspeptin and LH pulsatile temporal coupling in PCOS patients.

Authors:  Krzysztof Katulski; Agnieszka Podfigurna; Adam Czyzyk; Blazej Meczekalski; Alessandro D Genazzani
Journal:  Endocrine       Date:  2018-05-04       Impact factor: 3.633

6.  Polycystic ovary syndrome (PCOS) and kisspeptin - A Sri Lankan study.

Authors:  B Umayal; S N Jayakody; N V Chandrasekharan; W Ss Wijesundera; C N Wijeyaratne
Journal:  J Postgrad Med       Date:  2019 Jan-Mar       Impact factor: 1.476

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.